Novelion Therapeutics (Novelion Therapeutics) Growth Rank : 0 (As of May. 24, 2024)

View and export this data going back to 1988. Start your Free Trial

What is Novelion Therapeutics Growth Rank?

Novelion Therapeutics has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Novelion Therapeutics Growth Rank Related Terms

Thank you for viewing the detailed overview of Novelion Therapeutics's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Novelion Therapeutics (Novelion Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novelion Therapeutics Inc (OTCPK:NVLNF) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

c/o Norton Rose Fulbright, 1800 West Georgia Street, Suite 510, Vancouver, BC, CAN, V6B 0M3

Website

http://www.novelion.com

Headquartered in Vancouver, Canada, QLT is a biotechnology company that researches and develops products used to treat conditions of the eye. After a recent board change, QLT divested its only marketed product, a laser treatment called Visudyne for the treatment of wet age-related macular degeneration and subfoveal choroidal neovascularization. QLT also earns royalty payments on other certain previously divested products. Following recent pipeline changes, the company currently has one product in development for two rare eye conditions.

Executives

Kevin Kotler	10 percent owner	C/O BROADFIN CAPITAL, LLC, 300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Capital, Llc	10 percent owner	300 PARK AVENUE, 25TH FLOOR, NEW YORK NY 10022
Broadfin Healthcare Master Fund Ltd	10 percent owner	C/O 20 GENESIS CLOSE, ANSBACHER HOUSE, 2ND FLOOR, PO BOX 1344, GRAND CAYMAN E9 KY1-1108
Stonepine Capital, L.p.	10 percent owner	919 NW BOND STREET, SUITE 204, BEND OR 97703
Michael Dennis Price	officer: Chief Financial Officer
Benjamin Harshbarger	officer: See Remarks	ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142
Mark Dipaolo	director	660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
John J Orloff	director	C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015
Stephen L Sabba	director	DORSET MANAGEMENT CORP, 485 UNDERHILL BLVD SUITE 205, SYOSSET NY 11791
Mark Corrigan	director
Suzanne Louise Bruhn	director	C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
John C Thomas	director	8601 SIX FORKS ROAD, SUITE 160, RALEIGH NC 27615
Murray Stewart	officer: Executive Vice President, R&D	C/O NOVELION THERAPEUTICS INC., 1800-510 WEST GEORGIA STREET, VANCOUVER A1 V6B OM3
Jason Aryeh	director	11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
Mary T Szela	director, officer: Chief Executive Officer	10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121